Beta-blockers: Effects on bone mineral density and fracture risk

Current Rheumatology Reviews

Volumn 2, Issue 4, 2006, Pages 353-357

  Pérez Castrillón, José L ^a   Sanz Cantalapiedra, Alberto ^a   Dueñas Laita, Antonio ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

blocker; Bone markers; Bone mineral density; Fracture risk

Indexed keywords

ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEPTIN; PLACEBO; PROPRANOLOL;

ADRENERGIC SYSTEM; BONE DENSITY; BONE MASS; BONE METABOLISM; CASE CONTROL STUDY; CELL ACTIVITY; CLINICAL TRIAL; COHORT ANALYSIS; DRUG MECHANISM; DRUG USE; FRACTURE; HUMAN; HYPOTHALAMUS; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; SYMPATHETIC NERVE; SYMPATHETIC TONE; VASCULAR DISEASE;

EID: 33750736298     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339706778699878     Document Type: Review

References (33)

1. Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res 2000; 15: 1974-1980.
2. Bauer DC, Palermo L, Black D, Cauley JA. Quantitative ultrasound and mortality: a prospective study. Osteoporos Int 2002; 13: 606-612.
3. Togari A. Adrenergic regulation of bone metabolism: a possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech 2002; 58: 77-84.
4. Benavic JL, Bouvier M, Coren MG, Lefkowitz RJ. Regulation of adenyl ciclase-coupled beta adrenergic receptors. Annu Rev Cell Biol 1988; 4: 405-428.
5. Togari A, Arai M, Mizutami S, Koshihare Y, Nagatsu T. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteosacoma cells. Neurosci Lett 1997; 233: 125-128.
6. Kondo A, Togari A. In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria. Am J Physiol Endocrinol Metab 2003; 285: E661-E667.
7. Cherruau M, Fachinetti P, Baroukh B, Saffar JL. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone 1999; 25: 545-551.
8. Suzuki A, Palmer A, Bonjour JP, Carvezasio J. Cathecolamines stimulate the proliferation and alkaline phosphatase activity of MC3T3-E1 osteoblast like cells. Bone 1998; 23: 197-203.
9. Ducy P, Armling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100: 197-207.
10. Takeda S, Elefteriou F, Levassier R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111: 305-317.
11. Bonnet N, Benhamou CL, Brunet-Imbault B, et al. Severe bone alterations under β2 agonist treatments: Bone mass, michroarchitecture and strength analyses in female rats. Bone 2005; 37: 622-633.
12. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell 2005; 122: 803-815.
13. Elefteriou F, Takeda S, Ebihare K, et al. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 2004; 101: 3258-3263.
14. Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by sympathetic nervous system and CART. Nature 2005; 434: 510-520.
15. Murphy E, Williams GR. The thyroid and the skeleton. Clinical Endocrinology (Oxford) 2004; 61: 285-298.
16. Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005; 94: 15-21.
17. Chapurlatt RD, Duboeuf FP, Liens D, Meunier PJ, Dual Energy X-Ray Absorptiometry in patients with lower limb reflex sympathetic distrophy syndrome. J Rheumathol 1996; 23: 1557-1559.
18. Cavallo P, Maule S, Quadri R. Sympathetic nervous system, diabetes and hypertension. Clin Exp Hypertens 2001; 23: 45-51.
19. Rix M, Andreassen H, Eskildsen P. Impact of peripheral neuropathy on bone mineral density in patients with type 1 diabetes. Diabetes Care 1999; 22: 827-831.
20. Martín-Escudero JC, Pérez-Castrillón JL, Simal Blanco F, Arzua-Mouronte D, Bellido Casado J, Mena Martín J. Relación entre catecolaminas y masa ósea en población general. REEMO 2004; 13 (S1): 23.
21. Harada SH, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003; 423: 349-355.
22. Reid I, Lucas J, Wattie D, et al. Effects of a β-blocker on bone turnover in normal postmenopausal women. A randomized controlled trial. J Clin Endocrinol Metab 2005; 90: 5212-5216.
23. Mosekilde L, Jastrup B, Melsen F, et al. Effect of propanolol treatment on bone mass, bone mineral content, bone remodelling, parathyroid function and vitamin D metabolism in hyperthyroidism. Eur J Clin Invest 1984; 14:96-102.
24. Rejnmark L, Vestergaard P, Kassem M, et al. Fracture risk in perimenopausal women treated with Beta-blockers. Calcif Tissue Int 2004; 75:365-372.
25. Pasco J, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC. β-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 2004; 19: 19-24.
26. Reid I, Gamble GD, Grey AB, et al. β-blocker use, BMD, and fractures in the Study of Osteoporotic Fractures. J Bone Miner Res 2005; 20: 613-618.
27. Lavasseur R, Marcelli C, Sabatier JP, Dargent-Molina P. Beta-blocker use, bone mineral density and fracture risk in older women: results fron the Epidemiologie de L'Osteoporose Prospective Study. J Am Geriatr Soc 2005; 53: 550-552.
28. Bonnet N, Courteix D, Benhamou CL. Leptin, central nervous system and bone: influence of physical activity. Joint Bone Spine 2005; 72: 477-480.
29. Schoo K Sturkenboom M, Van Leeuwen J, Stricker B, Pols H. Use of Beta-Blockers is associated with BMD and fracture risk. Bone 2005; 36 (S2): 129-130.
30. Lynn H, Kwok T, Wong SYS, Woo J, Leung PC. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 2006 ; 38: 584-588.
31. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of β-blockers and risk of fractures. JAMA 2004; 292: 1326-1322.
32. De Vries F, Souverein PC, De Bruin ML, Cooper C, Van Staa TP, Leufkens HGM. Use of Beta-Blockers and risk of hip and vertebral fractures: associations with daily and accumulative dose. Bone 2005; 36 (S2): 130.
33. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nation wide case-control study. J Hypertens 2006; 24: 581-589.